GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (NAS:CDT) » Definitions » Cash Flow from Investing

Conduit Pharmaceuticals (Conduit Pharmaceuticals) Cash Flow from Investing : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Conduit Pharmaceuticals Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Conduit Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Conduit Pharmaceuticals gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Conduit Pharmaceuticals Cash Flow from Investing Historical Data

The historical data trend for Conduit Pharmaceuticals's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Cash Flow from Investing Chart

Conduit Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Cash Flow from Investing
- -0.18 0.73

Conduit Pharmaceuticals Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial - -0.24 - - -

Conduit Pharmaceuticals Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Conduit Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Conduit Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Conduit Pharmaceuticals  (NAS:CDT) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Conduit Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Conduit Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Conduit Pharmaceuticals's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Conduit Pharmaceuticals gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Conduit Pharmaceuticals's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Conduit Pharmaceuticals spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Conduit Pharmaceuticals's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Conduit Pharmaceuticals gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Conduit Pharmaceuticals's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Conduit Pharmaceuticals spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Conduit Pharmaceuticals's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Conduit Pharmaceuticals gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Conduit Pharmaceuticals's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Conduit Pharmaceuticals paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Conduit Pharmaceuticals's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Conduit Pharmaceuticals paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Conduit Pharmaceuticals's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Conduit Pharmaceuticals paid $0.00 Mil for other investing activities.


Conduit Pharmaceuticals Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Conduit Pharmaceuticals (Conduit Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4995 Murphy Canyon Road, Suite 300, San Diega, CA, USA, 92123
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Executives
Intelmed Llc other: See Responses 11421 GOLDEN EAGLE COURT, NAPLES FL 34120
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121
David Tapolczay director, officer: Chief Executive Officer 32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU
Andrew Regan director, 10 percent owner LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Algo Holdings, Inc. 10 percent owner, other: See Responses 100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309
Corvus Capital Ltd. 10 percent owner, other: See Responses WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107
Freda C Lewis-hall director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
James Bligh director 38 OXBERRY AVENUE, LONDON X0 SW6 5SS
Shaolin Capital Management Llc 10 percent owner 230 NW 24TH STREET, SUITE 603, MIAMI FL 33127
Richard Edward Feinberg director 2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103
Murphy Canyon Acquisition Sponsor, Llc 10 percent owner 4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123
Chele Chiavacci Farley director 4 RIDGE ROAD, TUXEDO PARK NY 10987
Bentzen Edwin H Iv officer: Chief Accounting Officer 2513 BIRCH HOLLOW ST, HENDERSON NV 89044
Jack Kendrick Heilbron director, officer: CEO, President, and Chairman 16433 BRONCO LANE, POWAY CA 92064